A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.
Leukemia
DRUG: MK0457
efficacy, 24 Months
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.